Henletor (torsemide) / Orchid - LARVOL DELTA

Effect of Serum Chloride Concentrations on Diuretic Effect in the TRANSFORM-Mechanism Mechanistic Study (KIDNEY WEEK 2025) - "In the TRANSFORM-Mechanism study we found no meaningful pharmacokinetic or pharmacodynamic advantages of torsemide versus furosemide. Increase in serum chloride concentration between visits was also associated with increased eGFR (r=0.317, p=0.013) and increased DE defined as natriuretic response normalized to diuretic dose (r=0.391, p=0.001). Conclusion Regardless of randomized diuretic or prescribed dose, increase in serum chloride concentration between study visits was associated with decreased serum renin concentration and increased eGFR and DE."

Cardiovascular • Congestive Heart Failure • Heart Failure

A Hidden Risk in the Loop: Furosemide-Triggered Hemolysis in Glucose-6-Phosphate Dehydrogenase Deficiency (KIDNEY WEEK 2025) - "Clinicians should consider G6PD deficiency in the differential diagnosis of unexplained hemolysis and remain vigilant regarding the potential oxidative risks of commonly used medications such as furosemide. When loop diuretic therapy is necessary, switching to a chemically related but structurally distinct agent like torsemide may offer a safer alternative in G6PD-deficient patients."

Anemia • Cardiovascular • Chronic Kidney Disease • Diabetes • Dyslipidemia • Hematological Disorders • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease • Type 2 Diabetes Mellitus • G6PD • HP

Daptomycin-Induced Hyperkalemia in the Absence of Creatinine Kinase Elevation: A Challenging Diagnosis in a Patient with Diabetes and Acute on Chronic CKD (KIDNEY WEEK 2025) - "Ten days prior to admission, her Cr increased from 1.5 to 1.83, and vancomycin was changed to daptomycin 600mg every 48 hours. Other pertinent home medications included cefepime 2g/d, torsemide 20mg/d, lisinopril 5mg/d, and metoprolol succinate 25mg/d...The daptomycin was changed to doxycycline on day 9, and within 48 hours, her K began to downtrend, normalizing at 72 hours while Cr was 3.08...As for this patient, it is important to consider this as her hyperkalemia was challenging to control with prolonged hospitalization prior to daptomycin discontinuation. Timely recognition of daptomycin-induced hyperkalemia should be considered in the differential to improve outcomes."

Clinical • Chronic Kidney Disease • Diabetes • Hematological Disorders • Metabolic Disorders

The Lonely Amyloid's Puzzle: Isolated Renal Apolipoprotein CII Amyloidosis - Familial or Isolated Occurrence? (KIDNEY WEEK 2025) - "Case Description A 63-year-old male with a history of Nephrotic CKD 3b complicated by pulmonary embolism on apixaban presented for proteinuria evaluation...He was started on losartan 25 mg and torsemide 10 mg...While some cases exhibit genetic underpinnings, including amino acid sequence variants and familial occurrence, the novelty of this case lies in the combination of its isolated renal involvement and the absence of protein structural abnormalities or detectable genetic mutations, particularly in the context of a family history of amyloidosis. Management remains primarily supportive."

Amyloidosis • Cardiovascular • Chronic Kidney Disease • Fibrosis • Genetic Disorders • Glomerulonephritis • Hepatology • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammation • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases

BRASH: A Vicious Cycle (KIDNEY WEEK 2025) - "He was taking metoprolol succinate 25 mg daily, sacubitril-valsartan 24-26 mg twice daily and torsemide 40 mg daily which were held on admission. As per a systematic review, over 50% cases had non-severe hyperkalemia (less than 6.5 mg/dL). With increasing use of beta blockers, ACE/ARBs and MRAs, the incidence of this syndrome will continue to increase and requires more awareness in the community."

Atrial Fibrillation • Cardiovascular • Chronic Kidney Disease • Coronary Artery Disease • Hypotension • Renal Disease

Comparing Loop Diuretic Efficacy and Safety in Patients with Acute Myeloid Leukemia and Differentiation Syndrome (ASH 2024) - "Patients were treated with furosemide (n=2,431), bumetanide (n=466), or torsemide (n=206), alongside glucocorticoids and allopurinol. This may be due to bumetanide's higher potency, rapid absorption, and shorter half-life, potentially increasing the risk of electrolyte imbalances and acute kidney injury. Conversely, furosemide may facilitate greater cumulative sodium excretion in patients with chronic renal insufficiency."

Clinical • Acute Kidney Injury • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Diabetes • Diabetic Nephropathy • Heart Failure • Hematological Malignancies • Hypertension • Leukemia • Metabolic Disorders • Nephrology • Oncology • Renal Disease

Comparison of the Efficacy of Torsemide and Furosemide in Managing Ascites Due to Liver Cirrhosis: A Systematic Review and Meta-Analysis (ACG 2025) - "Four randomized controlled trials involving a total of 98 participants, were included in the final analysis. 48 patients were treated with torsemide, while 50 patients were treated with oral furosemide. At the 24-hour mark, diuresis was more pronounced in the torsemide group (TG) compared to the furosemide group (FG), with a mean difference of 0.85 liters (95% CI 0.32-1.38, P=0.002, I2 =82%)."

Retrospective data • Review • Fibrosis • Gastroenterology • Hepatology • Immunology • Liver Cirrhosis

NEPHRON: A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (clinicaltrials.gov) - P3 | N=30 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial • Cardiovascular • Chronic Kidney Disease • Hypertension • Nephrology • Renal Disease

SICKLE CELL DISEASE LEADING TO DEBILITATING PULMONARY ARTERIAL HYPERTENSION (CHEST 2025) - "Managing SCD-associated PH primarily focuses on treating the underlying disease with hydroxyurea or chronic blood exchange transfusions, along with anticoagulation for thromboembolism and treatment of left heart failure in those with post-capillary PH...Given clinical volume overload, she was started on torsemide...Although intended to be started on macitentan (an endothelin receptor antagonist), she returned to the hospital with worsening dyspnea before she could get the medication approved...She then became increasingly hypotensive riociguat was uptitrated, requiring initiation of midodrine as well as downtitration of diuresis... SCD-associated PH carries a high mortality risk with a notable lack of evidence on effective therapy options that demonstrate significantly improved outcomes."

Cardiovascular • Congestive Heart Failure • Genetic Disorders • Heart Failure • Hematological Disorders • Hypotension • Pulmonary Arterial Hypertension • Respiratory Diseases • Sickle Cell Disease

Optimal Diuretic Strategies for Chronic Heart Failure. (PubMed, Med Clin North Am) - "Optimizing guideline-directed medical therapy (GDMT), particularly angiotensin receptor-neprilysin inhibitors, sodium-glucose cotransporter 2 inhibitors, and mineralocorticoid receptor antagonists, may support diuretic minimization. Integrating GDMT with tailored monitoring may improve loop diuretic use and improve clinical outcomes in chronic heart failure management."

Journal • Review • Cardiovascular • Congestive Heart Failure • Heart Failure

EFFICACY OF ORAL TORSEMIDE VERSUS ORAL FUROSEMIDE IN MANAGEMENT OF EDEMA IN PATIENTS WITH NEPHROTIC SYNDROME: AN OPEN-LABEL SUPERIORITY RANDOMIZED CONTROLLED TRIAL (ESPN 2025) - "Torsemide is not superior to furosemide in inducing diuresis in children with nephrotic syndrome with moderate to severe edema."

Clinical • Head-to-Head • Acute Kidney Injury • Cardiovascular • Congestive Heart Failure • Glomerulonephritis • Heart Failure • Metabolic Disorders • Nephrology • Renal Disease

Randomized controlled trial on efficacy and safety of torsemide versus furosemide in patients with nephrotic syndrome. (PubMed, Pediatr Nephrol) - "Torsemide is not superior to furosemide in inducing diuresis in children with nephrotic syndrome with moderate to severe edema."

Journal • Cardiovascular • Congestive Heart Failure • Glomerulonephritis • Heart Failure • Nephrology • Renal Disease

A PROSPECTIVE RANDOMIZED CONTROLLED, OPEN LABELED, TWO ARM PILOT STUDY WITH BLINDED ENDPOINTS TO EVALUATE THE EFFICACY OF TORSEMIDE-SPIRONOLACTONE VERSUS FUROSEMIDE-SPIRONOLACTONE COMBINATION IN CIRRHOSIS PATIENTS WITH NEWLY DIAGNOSED ASCITES (AASLD 2025) - "Both the FS and TS combinations were equally effective in achieving ascites control, with significant reductions in abdominal girth and mean body weight. No significant differences were observed between the groups in terms of efficacy, safety or survival. The findings suggest that both the regimens are equally effective and well tolerated for the management of new onset ascites."

Clinical • Cardiovascular • Diabetes • Fibrosis • Gastroenterology • Gestational Diabetes • Heart Failure • Hepatology • Immunology • Liver Cirrhosis • Metabolic Disorders

Rescue with Impella 5.5 after HeartMate 3 failure: a bridge to heart transplant (HFSA 2025) - "Home medications: aspirin 81mg OD, hydralazine 100mg QID, nifedipine 60mg BID, Entresto 24/26mg BID, torsemide 20mg OD, and warfarin 6mg OD (INR 2.6)...Bivalirudin 0.12 mg/kg/hr was initiated while inpatient...Milrinone 0.25 mcg/kg/min was initiated...He was intubated and started on meropenem 2mg IV TID... This case highlights the feasibility of Impella 5.5 support after HM3 failure as BTT for short-term hemodynamic stabilization in the setting of LVAD outflow obstruction and cardiogenic shock without the need for ECMO."

Cardiomyopathy • Cardiovascular • Chronic Kidney Disease • Cough • Diabetes • Diabetic Nephropathy • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Pneumonia • Respiratory Diseases • Transplantation

Time On Oral Diuretics Prior To Hospital Discharge And Rates Of Hospital Readmission (HFSA 2025) - "In patients with ADHF, monitoring patients on oral diuretics for /= 24 hours did not impact 30-day heart failure readmission rates. Future studies should investigate the relation between time on oral diuretics and overall response to oral diuretics before discharge. Lengthier time on oral diuretic prior to discharge may reflect poor diuretic response and/or failure to respond at all."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Metabolic Disorders • Myocardial Infarction

DOCK: Diuretics and Volume Overload in Early CKD (clinicaltrials.gov) - P4 | N=46 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Oct 2025 ➔ Dec 2025 | Trial primary completion date: Sep 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Hypertension • Nephrology • Renal Disease

Outpatient diuretic use in patients with baroreflex activation therapy (ESC-WCC 2025) - "Furosemide equivalents were calculated utilizing the following oral conversion: furosemide 80mg to torsemide 20mg to bumetanide 1mg. The use of baroreflex activation therapy in HFrEF patients leads to a reduction in diuretic utilization. Further prospective evaluation is warranted to confirm these results and to determine if diuretic reduction with BAT is associated with improved clinical outcomes."

Clinical • Reflex • Cardiovascular • Congestive Heart Failure • Heart Failure

Time to refractory congestive heart failure in cats presenting with pleural effusion vs. pulmonary edema. (PubMed, J Vet Cardiol) - "In this study sample, cats with pleural effusion have a reduced time to refractory CHF and survival times compared to cats with pulmonary edema."

Journal • Pleural effusion • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Respiratory Diseases

Clinical evaluation of a novel fixed-dose combination tablet (Sentorphil® ForteGold) versus compounded powdered medications in dogs with myxomatous mitral valve disease: a randomized, double-blind study. (PubMed, Front Vet Sci) - "In a randomized, double-blind clinical trial, 60 client-owned dogs diagnosed with ACVIM stage C MMVD were assigned to receive either a novel fixed-dose combination tablet (Sentorphil® ForteGold) or a compounded powdered mixture of torsemide, pimobendan, enalapril, and spironolactone. Its formulation ensures accurate dosing, improved owner compliance, and enhanced clinical outcomes. Further studies with larger populations and extended follow-up periods are warranted to confirm these findings."

Clinical • Journal • Cardiovascular

DOCK: Diuretics and Volume Overload in Early CKD (clinicaltrials.gov) - P4 | N=46 | Recruiting | Sponsor: VA Office of Research and Development | Trial completion date: Jul 2025 ➔ Oct 2025

Trial completion date • Cardiovascular • Chronic Kidney Disease • Congestive Heart Failure • Hypertension • Nephrology • Renal Disease

Comparative analysis of furosemide and torsemide efficacy in 24 hours of acute heart failure admission. (PubMed, Front Pharmacol) - "Daily urine output after 24 h of treatment reached an EMM of 3,559.67 mL in the furosemide group, and 2,734.89 mL in the torsemide group (p = 0.068). Both furosemide and torsemide demonstrated comparable efficacy in the initial treatment of AHF, as assessed by laboratory, ultrasound, and clinical parameters."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Pulmonary Disease

Postpartum Diuretics for Hypertensive Disorders of Pregnancy: A Systematic Review and Meta-analysis. (PubMed, Obstet Gynecol) - "Diuretics were associated with a reduction in immediate postpartum hypertension in individuals with hypertensive disorders of pregnancy (NNT 4), although this reduction was not observed when analysis was restricted to trials at low risk of bias. Further studies are needed to assess the role of diuretics in treating postpartum hypertension."

Journal • Retrospective data • Cardiovascular • Hypertension

Reassessing Loop Diuretic Strategies in HFrEF: A Case for Preferential Torsemide Use? (PubMed, Cardiology) - No abstract available

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Loop Diuretic Dose and Nutritional Status of Patients with Heart Failure with Reduced Ejection Fraction. (PubMed, Nutrients) - "Patients were divided into three groups according to the daily dose of loop diuretics (defined as furosemide equivalent = 1 × furosemide dose and 2 × torsemide dose): low dose (LD), 40 mg/day or no treatment; medium dose (MD), 41-160 mg/day; or high dose (HD), >160 mg/day. For CONUT, the differences were significant between all groups: nutritional status was the worst in the HD group, intermediate in the MD group, and the best in the LD group. The intake of loop diuretics, especially in high doses, correlates with an elevated risk of malnutrition in patients with HFrEF independently of sex, age, NYHA class, and left ventricular ejection fraction."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

Bioavailability and Bioequivalence Study of Extended Release Torsemide and Spironolactone (clinicaltrials.gov) - P3 | N=24 | Recruiting | Sponsor: Sarfez Pharmaceuticals, Inc.

New P3 trial